Apogee Therapeutics (APGE) Current Assets (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Current Assets data on file, last reported at $1.1 billion in Q1 2026.

• Quarterly Current Assets rose 105.89% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 105.89% YoY) and the FY2025 annual result came in at $741.4 million, up 39.95% from the prior year.
• Current Assets climbed to $1.1 billion in Q1 2026 per APGE's latest filing, from $741.4 million in the prior quarter.
• Across five years, Current Assets topped out at $1.1 billion in Q1 2026 and bottomed at $130.7 million in Q2 2023.
• The 5-year median for Current Assets is $529.7 million (2024), against an average of $543.6 million.
• The widest annual swing landed in 2024, when Current Assets soared 421.82%; it then plunged 36.45% in 2025.
• Tracing APGE's Current Assets over 5 years: stood at $152.1 million in 2022, then jumped by 162.02% to $398.4 million in 2023, then soared by 32.96% to $529.7 million in 2024, then soared by 39.95% to $741.4 million in 2025, then jumped by 44.84% to $1.1 billion in 2026.
• Per Business Quant, the three latest APGE Current Assets figures stand at $1.1 billion (Q1 2026), $741.4 million (Q4 2025), and $540.1 million (Q3 2025).

Peer Comparison